1
. Thus, cells contain three classes of Ub: free, thioester-activated and (iso)peptide conjugated. Because ubiquitination contributes to the regulation of nearly every cellular process, Ub availability must be tightly controlled. Contributions to Ub homeostasis include Ub expression as peptide or protein fusions and as polyubiquitin, processing to generate monoUb and recycling from Ub-protein conjugates by deubiquitinating enzymes (DUBs) 2 . Perturbations of these processes can deplete cellular free Ub and cause defects in cell development or neuronal functions [2] [3] [4] [5] [6] [7] [8] [9] and inhibit cell proliferation 10, 11 . Conversely, transgenic mice overexpressing Ub by just two-or three-fold exhibit neurological abnormalities 12 .
Although the need to regulate free Ub is well established, studying intracellular Ub pools has been difficult. One approach has been ectopic expression of GFP-tagged Ub 13 , but such experiments can be complicated by perturbations to the regulation of endogenous Ub and non-physiological behavior of the tagged Ub. For example, C-terminal tags would prevent Ub activation and conjugation, and N-terminal tags would block assembly of all M1-linked polyUb conjugates. Typically, to quantify endogenous free, conjugated or total Ub, anti-Ub antibodies in conjunction with ELISA or western blots are used. However, there are major drawbacks. Due to the high structural diversity of polyUb and Ub-protein conjugates 14 , binding efficiencies for the different Ub conjugates can vary widely. Moreover, for western blots, dynamic range is inherently very limited and reproducibility can be problematic. Recently, Ub protein standard absolute quantification (Ub-PSAQ) mass spectrometry (MS) has been described to quantify free and conjugated Ub from cell lysates 15 . However, Ub-PSAQ does not resolve the pool of thioester-activated Ub, and its dependence on sophisticated instrumentation and affinity-isolation steps makes its implementation challenging for most laboratories. Finally, none of the aforementioned approaches allow real-time quantitation of free Ub as it changes, for example, in deubiquitination reactions.
With the dual goals of establishing a simple, reliable method to quantify cellular Ub pools as well as a versatile real-time DUB assay, we embarked on development of sensors for free Ub. Our strategy was to fuse Ub binding domains (UBDs) of known structures that bind to non-overlapping Ub surfaces, and to exploit avidity effects to achieve high affinity and selectivity. To convert the binding proteins into sensors, we attached fluorescent dyes whose intensities changed in response to Ub binding. We then used the sensors to measure free, activated and conjugated intracellular Ub, to quantify deubiquitination of unlabeled conjugates in real-time and to identify endogenous free Ub by fluorescence microscopy of fixed cells.
Results
Design and characterization of the sensors. Ub binding proteins were assembled from multiple UBDs linked in tandem. Interdomain peptide linkers were kept short to promote avidity while minimizing the entropic cost of binding. Most UBDs bind through interactions with one of three different Ub surfaces: the hydrophobic patch surrounding residue I44, the C-terminal tail and the surface around D58 (Fig. 1a, upper panel) . Individually, UBDs bind Ub with only modest affinities (K d = 10 −5 to 10 −3 M), but by linking two or three weak-binding UBDs that target distinct surfaces, we predicted that high affinity could be achieved. An early version of an avidity-based binder that we call tIVR employed IsoT Buz 
, Vps27
UIM and Rabex5
Ruz domains fused with flexible linkers (Fig. 1a , lower left panel and Supplementary Fig. 1 ). The IsoT Buz domain (K d = 3 μM) 16 , which binds primarily to Ub C-terminal residues, conferred selectivity for free Ub, whereas the Vps27 UIM (K d = 117 μM) 17 and Rabex5 18, 19 domains worked synergistically with IsoT Buz to increase overall affinity and specificity.
To measure the affinity between tIVR and free Ub, we first titrated Atto532-Ub(S20C) with tIVR and determined a 0.4 nM K d for the 1:1 complex (Supplementary Fig. 2a) . Then, taking advantage of this high affinity and the 3.5-fold lower fluorescence of Atto532-Ub(S20C) in the complex, we determined tIVR affinities for Ub and other ligands by competition (Fig. 1b) . We found that free Ub binds tIVR with a K d of 19 nM (measured as an inhibition constant K i , see Fig. 1b) ; the higher affinity of Atto532-Ub(S20C) indicates that the dye promotes the interaction (ΔG ≈ −0.2 kcal mol
−1
). The competition assays additionally showed that tIVR has high selectivity against the Ub-like (UbL) protein Nedd8 and Ub derivatives that lack a free C-terminal carboxylate (Fig. 1b) . Among the many different UbL proteins in eukaryotes 20 , Nedd8 is most similar to Ub in its sequence and tertiary structure, and its C-terminal four amino acids are identical 21 ; nonetheless, tIVR has a 3,000-fold preference for Ub. A similarly large discrimination was observed against Ub-GB1, a mimic of a Ub-protein conjugate in which the Ub C terminus is extended by the Protein G B1 domain, and even addition of the small adduct hydrazine to the Ub C terminus decreased tIVR affinity 150-fold (Fig. 1b) .
To provide a direct readout for Ub binding, we explored sitespecific labeling with fluorescent dyes (Supplementary Fig. 3 ). tIVR(C130) modified with Atto532-maleimide showed a threefold fluorescence increase on Ub binding ( Supplementary Fig. 2b ).
By replacing Vps27
UIM with the S5a UIM domain and introducing two amino acid substitutions in the IsoT Buz domain (Fig. 1a and Supplementary Fig. 1 ), we developed a second-generation sensor, tISR, with nearly ten times the affinity of tIVR for free Ub ( Supplementary Fig. 2c,d ). Atto532-tISR fluorescence increased (Fig. 1c and Supplementary Fig. 2b) . A third-generation sensor was developed with the goal of even greater affinity. In tUI, the UIM-RUZ domains of tIVR/tISR were replaced by ubiquilin-1 associated UBA (UQ1 UBA ), which binds to the Ub hydrophobic patch (K d = 22 μM) 22, 23 . Only two amino acids (versus five with tIVR or tISR) were needed to connect the UQ1 UBA C terminus with the N terminus of IsoT Buz , which we expected might reduce the entropic cost of complex formation. We conjugated Atto532 to UQ1 UBA G573C in tUI (Fig. 1a , lower right panel); titration with Ub revealed a three-fold fluorescence increase and a remarkably low K d of 66 ± 16 pM (Fig. 1d,e) . We confirmed this by measuring the association and dissociation rate constants for the Atto532-tUI-Ub complex, from which we calculated a K d of 56.4 ± 1.2 pM ( Supplementary Fig. 4 ). To our knowledge, this high affinity is unprecedented for binding to a single Ub. Atto532-tUI was selective against Ub C-terminal conjugates, preferring free Ub over Ub-GB1 by >10 6 and having 120-fold higher affinity for Ub than Nedd8. The greater selectivity against Nedd8 by the tIVR/ tISR sensors can be attributed to their Ruz domain, which is absent from tUI. Nonetheless, as described below, tUI's selectivity and high affinity make it the first choice for most in vitro applications.
In cells, multiple forms of Ub can have a free C terminus and the proximal Ub of free or 'unanchored' polyUb chains could be recognized by the Buz domain. Inspection of the sites on Ub used for Ub-Ub linkages (that is, Ub's seven lysine ε-amines plus the M1 α-amine) showed that they are not occluded when bound by the various UBDs used in the sensors (Fig. 1a) . These models are consistent with studies that have shown little or no discrimination by individual UBA, UIM or Buz domains for binding Ub in chains with different Ub-Ub linkages 16, 22, 23 . Accordingly, competition by Ub 2 or Ub 4 representing all eight Ub-Ub linkages revealed little difference from free monoUb in binding to tIVR (Fig. 1e,f) . Based on findings of linkage-independent binding by UBA domains 22, 23 and the small tUI footprint modeled onto Ub (Fig. 1a) , we anticipate similar linkage-independent binding by tUI to unanchored polyUb.
Another Ub modification that potentially could affect detection by the sensors is phosphorylation. Multiple Ub serine and threonine phosphosites have been identified 24 ; as with Ub lysines, most of these do not overlap with the surfaces bound by the sensor UBDs (Fig. 1a) . Ub phosphorylation on S65, which has functions in Ub-mediated signaling and mitophagy, has been the most intensively studied phosphoUb species [25] [26] [27] [28] . Titration of Atto532-tUI with Ub(pS65) indicated four-fold weaker binding than with Ub (Fig. 1d,e) . Wauer et al. have shown by nuclear magnetic resonance that Ub(pS65) exists in an equilibrium between two principal conformers 29 . One form (~70%) is essentially like unmodified Ub, whereas in the minor conformer (~30%) movement of the β5 strand retracts the normally extended C-terminal residues and displaces a key component of the hydrophobic patch. Because interactions with Buz and UBA domains are likely to be disrupted in the minor conformer, the Ub versus Ub(pS65) K d difference could in part reflect this equilibrium where only a fraction of Ub(pS65) is in the binding-competent conformation.
Real-time deubiquitination assays with label-free substrates.
Although desirable, quantitative DUB activity assays rarely employ physiological substrates and have been hampered by the lack of good methods to quantify products. Moreover, real-time monitoring of activity-the preferred approach to high-precision kinetics studies-has been virtually impossible with physiological DUB substrates. For these reasons, artificial substrates such as Ub-(7-amido-4-methylcoumarin) or conjugates (for example, diUb) modified with fluorophores for fluorescence resonance energy transfer-(FRET-) based assays are used 30, 31 . Our free Ub sensors make possible less restrictive DUB assays that can employ virtually any Ub conjugate as a substrate. As an example, we used Atto532-tIVR to monitor DUBcatalyzed release of free Ub (or unanchored polyUb) in a continuous fluorometric assay. As a substrate, we used K48-linked Ub 5 conjugated to ovomucoid first domain (OM); the ovomucoid first domain moiety also was modified with Lucifer Yellow dye (LY) for detection after SDS-PAGE 32 . For the DUB, we used human OTUB1, which selectively cleaves K48 Ub-Ub linkages 33 and is activated allosterically by certain E2 enzymes 34 . Without OTUB1, Ub 5 OM(LY) and Atto532-tIVR showed no fluorescence change, whereas enzyme addition initiated a fluorescence increase corresponding to release of (poly)Ub (Fig. 2) ; as expected, addition of UbcH5c stimulated the deubiquitination activity 34 . SDS-PAGE confirmed the sensor results ( Supplementary Fig. 5 ). Because OTUB1 cleaves only K48 Ub-Ub linkages, Ub 1 -OM(LY) accumulated on OTUB1 digestion, even with UbcH5c (lane 6, Supplementary Fig. 5a -c). This remaining conjugated Ub could be cleaved by the non-specific DUB Usp2cc (lane 7, Supplementary Fig. 5a -c). The release of free (poly)Ub determined in real-time using the sensor agreed with the amounts calculated by quantifying the LY-labeled gel bands ( Supplementary Fig. 5d ).
Ub pool quantitation in cell lysates. We next developed methods using the sensors to quantify cellular Ub pools. Our goal was to generate a workflow that would not depend on expensive, timeintensive steps requiring chromatography or MS. The general approach, in which sensor (for example, Atto532-tUI) fluorescence is measured with and without addition of cell lysate or other sample, promised to be simple and direct. The main challenge was to develop conditions to prevent appearance of free Ub due to disassembly of conjugates by endogenous DUBs or from spontaneous hydrolysis of Ub thioesters.
Our strategy was to lyse cells and quickly inactivate endogenous DUBs and other proteases, and then treat each sample in three ways to differentially convert Ub pools to the free-Ub form for measurement with the sensor (Fig. 3a) . To measure endogenous free Ub without interference from chemically labile Ub thioesters, samples were treated with hydrazine to rapidly convert all Ub thioesters into Ub C-terminal hydrazide; Ub-hydrazide is stable and, relative to free Ub, gives a negligible response with the sensor (Fig. 1b-e and Supplementary Fig. 6 ). Thus, sensor fluorescence of hydrazinetreated samples will measure endogenous free Ub. With a second portion of the sample, β-mercaptoethanol was used to release Ub from thioesters; measurement with the sensor then will report the sum of the endogenous free and thioesterified Ub pools 35 . A third portion was incubated with Usp2cc, a truncated DUB that can deubiquitinate virtually all forms of conjugated Ub 36 ; when used in combination with a thiol reducing agent, all forms of Ub are converted to free Ub ( Supplementary Fig. 7 ) and the sensor readout will report the total Ub. By deducting the sum of the thioester-activated and free Ub from the total Ub, we can quantify the conjugated-Ub pool.
We first determined the amounts of free, activated and conjugated Ub in HeLa cells (Fig. 3) ; the results are in good agreement with other reports 15, 37, 38 . The sensor assays then were used with HeLa cells treated with inhibitors of the E1 Ub-activating enzyme or proteasome (Fig. 3b,c) . As expected 39 , the E1 inhibitor C1 dramatically increased free Ub with a concomitant loss of activated Ub and most Ub-protein conjugates (Fig. 3b) . Conversely, proteasome inhibition by bortezomib (BTZ) promoted accumulation of Ub conjugates that reached a maximum at 1 h and then persisted through a 4 h treatment ( Fig. 3c and Supplementary Fig. 8 ). The conjugate increase was accompanied by a modest depletion of activated Ub and a two-fold decrease in free Ub, presumably due to impaired proteasome-dependent recycling of Ub from conjugates. Different from this result, proteasome-inhibited mouse embryonic fibroblast (MEF) cells exhibited little change in free Ub levels, even though conjugated Ub increased 50%; instead total Ub increased, likely due to increased expression of Ub genes (Fig. 3c) 
.
Quantitation of endogenous free Ub in fixed cells. Atto532-tUI, with its high affinity and specificity, could be an ideal tool to localize endogenous, intracellular free Ub. Initially, fixed cells were stained directly with Atto532-tUI, but high background fluorescence, possibly from non-specific binding by the fluorophore, reduced sensitivity (data not shown). Therefore, we used instead hemagglutinin-tagged tUI (HA-tUI) followed by detection with anti-HA antibody. We confirmed the specificity of HA-tUI in control experiments where fixed cells were incubated with HA-tUI together with excess free Ub. The fluorescence observed in these competition experiments was negligible, suggesting that the staining with HA-tUI is specific for cellular Ub (Supplementary Fig. 9 ). A diffuse intracellular distribution of free Ub was expected based on its small size (8.6 kDa) and negligible self-association 41 . Staining with HA-tUI was observed throughout the cytoplasm and nuclei of HeLa, U2OS, MEF and retinal pigment epithelium (RPE)1 cells (Fig. 4a) . Compared to K48-linked chains and (poly)ubiquitylated proteins, free Ub staining appears evenly distributed throughout the cell (Supplementary Fig. 10 ). GFP-Ub mutated to prevent its conjugation to other proteins was similarly diffuse when expressed in mammalian cells 13 . Staining with HA-tUI offers an alternative to solution-based assays to monitor changes in free Ub during growth or in response to different stresses. After proteasome inhibition with BTZ for 1 h, HeLa, U2OS, MEF and RPE1 cells showed 1.3-1.5-fold less staining with HA-tUI relative to control cells. As expected, E1 inhibition increased the free Ub (two-fold in MEF and RPE cells; three-fold in HeLa and U2OS cells) (Fig. 4b,c) . Although proteasome inhibition decreased free Ub in all four cell lines, the intracellular distributions of free Ub appeared unaffected. For RPE1 cells, ratios of cytoplasmic to nuclear staining were not changed by incubation with BTZ (control cells, 0.85 ± 0.07, n = 5; BTZ, 0.89 ± 0.08, n = 4), whereas increased staining was observed after E1 inhibition and cell-to-cell variability was greater overall (Fig. 4a-c) . The changes in staining of HeLa cells are consistent with the in-solution assays, although MEF cell staining indicated ~25% less free Ub after proteasome inhibition than was determined by the in-solution assays (Figs. 3c and  4a-c) . Possibly, because hydrazine treatment was not used with the imaged cells, some free Ub detected by staining could have arisen from spontaneous hydrolysis of Ub thioesters, thereby inflating the 'free' Ub and confounding direct comparison of the two assays. Staining with tUI also revealed cell cycle-dependent differences in free Ub levels. RPE1 cells undergoing mitosis bound 1.6-fold more HA-tUI than cells in interphase (Fig. 4d) . The increase in free Ub may be due, at least in part, to large-scale deubiquitination of H2A histones in mitotic cells 42 . discussion Individually, UBDs have only modest affinity for Ub and are typically found together with other binding domains (and sometimes additional UBDs) to promote binding to specific types of (poly)Ubprotein conjugates. By fusing multiple UBDs, we have engineered new proteins with specificity and high affinity for monomeric free Ub that have been shown to be uniquely suited for in vitro sensing of free Ub. Our basic strategy was to use the Buz domain to direct binding to Ub with an unconjugated C terminus, and to increase affinity with one or two additional UBDs that interact with Ub on non-overlapping surfaces. Critical to this design strategy was maximizing avidity. This was achieved by having multiple UBDs bind simultaneously while minimizing the entropy lost on complex formation through careful selection of peptides linking the UBDs. Avid binding can boost affinity by combining the contributions of individual binding domains in a complex assembled from a multivalent ligand and a corresponding multivalent binder. The Gibbs free energy for binding overall (ΔG total ) can be approximated as the sum of the individual binding domain interaction free energies (ΔG BD1 , ΔG BD2 and so on) plus the unfavorable free energy due to reduction in entropy (predominantly, losses in translational and rotational entropy) from having all the binding domains linked together (ΔG S ) 43 :
total B D1 BD2 B Dn S To achieve 'perfect' avid binding and maximize affinity, ΔG S should be close to zero. For Ub binding by a tandem-UBD (tUBD) protein such as tIVR: (Fig. 1e) . Thus, although avidity promotes tight binding by tIVR, it is at the cost of ΔG S , which is 16 domains. Contributing to this highly efficient avidity effect is that tUI has only one linker peptide (versus two in tIVR), and it is very short ( Supplementary  Fig. 1 ). Thus, a likely route to increase affinity for tIVR or tISR is further optimization of the interdomain linkers. On the other hand, a large increase in tUI's affinity would have to come from tighter-binding versions of one or both UBDs, as the linker already is nearly optimal.
There are several ways in which our free Ub sensors could be improved. Affinity might be increased, as noted above, with either modified linkers or alternative UBDs. Our designs have utilized only a few of more than 20 types of UBD 44, 45 ; moreover, other Ub binding proteins such as catalytically inactive DUBs might be used as components of tUBD-type fusion constructs 46 . Particularly intriguing is the prospect of tailoring recognition by incorporation of a UBD that would select either for or against specific modifications on the Ub. For example, although tIVR binds equally well to free polyUb chains of different Ub-Ub linkage types (Fig. 1f) , modified Ruz or UIM domains could be developed in which steric clash prevents binding to Ub conjugated at particular lysine(s). Similarly, UBD (or linker) modifications might add selectivity for phosphoUb derivatives. Finally, alternative fluorophores and attachment sites can be explored to improve sensor sensitivity and dynamic range.
The free Ub binders and the fluorescent sensors developed from them provide new tools to capture, deplete, quantify or visualize free Ub in vitro and in cells. Multiple DUBs have been implicated in human disease 47 , but DUB inhibitor screens generally have been limited to non-physiological substrates. The real-time sensor-based assays will make possible high-throughput screens with virtually any Ub conjugate as the substrate. Other examples include neurological disorders where Ub homeostasis is disrupted and accompanied by Ub-containing aggregates or a general depletion of free Ub. Staining by tUI offers a new approach to examine neurons at the single-cell level to study the effects of genetic or environmental perturbations on Ub homeostasis and intracellular distribution. Extracellular free Ub is of interest as well, as it has been suggested as a biomarker for trauma and disease 48 ; here also, the sensors can replace the less specific antibody-based assays typically used.
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were prepared as described. OTUB1 was a gift from C. Wolberger (Johns Hopkins University). K6, K11, K27, K29, K33, K48 and K63-linked Ub 2 chains were purchased from UbiQ Bio, Ub(pS65) was from Boston Biochem and M1-linked Ub 4 was prepared as described 51 .
Synthesis of Ub-hydrazide. Ub (1.5 mM) was incubated with 10 mM ATP, 10 mM MgCl 2 , 100 mM sodium 2-mercaptoethanesulfonate (MESNA, Fluka) and 100 nM mouse E1 in 20 mM HEPES (pH 8.0) for 3 h at 37 °C to form Ub-MESNA thioester (confirmed by MS; see Supplementary Fig. 6b ). The Ub-MESNA then was incubated in 300 mM aqueous hydrazine for 30 min at 37 °C to form Ub-hydrazide. The reaction product was diluted 25-fold with 50 mM ammonium acetate, adjusted to pH 4.5 (Buffer B) and purified by cation-exchange chromatography on a Mono S column (GE Healthcare, no. 17-0547-01). The column was washed with 20 volumes of Buffer B and eluted with a linear gradient of 0-1 M NaCl in the same buffer. The purified Ub-hydrazide was confirmed by MS ( Supplementary Fig. 6b ).
Fluorophore labeling. Sensor proteins were labeled at cysteine with fluorophoremaleimide dyes from ATTO-TEC (Atto dyes, see Supplementary Fig. 3 ), Molecular Probes (Alexa Fluor 488) or Anaspec (fluorescein). Fluorophore-maleimide dyes (1.5-5-fold molar excess) were incubated with 50 μM sensor in 50 mM HEPES, pH 7.4, 100 mM NaCl for 2 h at 25 °C. Excess dyes were quenched by incubation with 10 mM β-mercaptoethanol for 10 min at 25 °C. To remove excess dyes, the reaction product was bound to Ni-NTA resin (Thermo Fisher) equilibrated with Buffer A, the resin was washed five times with the Histrap binding buffer, and sensor proteins were eluted with Histrap elution buffer. Labeling was confirmed by SDS-PAGE and then scanning the gel for fluorescence using a Typhoon FLA 9500 (GE Healthcare Life Sciences). Degree of labeling (DOL) and concentrations of the labeled proteins were calculated by the equations below. In the equations, A m represents the absorbance at the dye absorption maximum, A 280 is absorbance at 280 nm of the labeled protein, ε prot is the extinction coefficient at 280 nm of the protein, ε 280 is the extinction coefficient at 280 nm of the dye alone, ε m is the extinction coefficient at the absorption maximum of the dye and CF 280 is the correction factor at 280 nm.
Binding assays. All binding assays were done in PBS buffer, pH 7.4, supplemented with 0.05% Brij35 and either 0.2 mg ml −1 ovalbumin or GB1 protein, and either 1 mM DTT or 1 mM TCEP. A FluoroMax-4 spectrofluorimeter (HORIBA Scientific) was used to measure fluorescence intensity in the binding assays. K d and K i values were calculated by fitting with a single-site binding model 52 using Prism 6 (GraphPad Software). Because of its high affinity for Ub, only 10 pM Atto532-tUI was used in the binding assays to keep its concentration below the K d . To improve detection of the fluorescence from this low concentration of Atto532-tUI, we increased the assay volume to 2.7 ml. The stock Ub titrated into the solution was ≤1.5% of the total volume.
Stopped-flow kinetics. To determine the k off and k on rates of Atto532-tUI with free Ub, rapid kinetics were monitored by fluorescence using a MOS-500 spectrometer equipped with a SFM-4000 mixer (Bio-Logic Science Instruments) maintained at 25 °C. The excitation wavelength was set to 530 nm with a 5 nm bandwidth, and the fluorescence emission was detected with a 540-620 nm bandpass filter.
Real-time DUB assays.
A Fluoromax-4 spectrofluorimeter (HORIBA Scientific) was used to monitor fluorescence of samples (45 μl) in ultramicro quartz cuvettes (Hellma) at 25 °C. The buffer was PBS, pH 7.4, with 0.05% Brij35, 0.2 mg ml −1 ovalbumin and 1 mM DTT. A standard curve was generated to convert change in sensor fluorescence to the corresponding free Ub concentrations; for example, 2 nM Atto532-tIVR was titrated with 2, 3, 6, 10, 18 and 32 nM Ub, and the binding curve was fit as described above. Fluorescent intensities from real-time DUB assays then were converted to free Ub concentrations using the fitted binding equation. For deubiquitination of Ub 5 -OM(LY), results were confirmed by SDS-PAGE of samples from the reaction mixtures and fluorescence imaging of the gel with a Typhoon FLA 9500 laser scanner (GE Healthcare Life Sciences).
In-solution Ub pool assays. Sample preparation. Cells were lysed in 100 mM MOPS, pH 6.0, 8 M urea, 20 mM NEM and EDTA-free Complete protease inhibitors (Roche) by sonication and then centrifuged at 15,800g. Total protein in the clarified extract was measured using the bicinchoninic acid assay before being divided into three fractions for treatment with Usp2cc, β-mercaptoethanol or hydrazine. The fraction to be treated with Usp2cc was diluted with digestion buffer (25 mM HEPES, pH 7.5, 140 mM NaCl and 10 mM DTT) to reduce the urea to less than 2 M; to this, Usp2cc was added at a 1:10 (Usp2cc:total protein) ratio and incubated at 37 °C for 1 h. To another fraction of the extract, 100 mM CHES, pH 9, containing 150 mM β-mercaptoethanol was added and incubated at 37 °C for 1 h. The third fraction was incubated at 37 °C for 1 h with freshly made 200 mM hydrazine-HCl, pH 8.5. These samples were then diluted using PBS and 0.2 mg ml −1 ovalbumin to insure that Ub was within the linear range of the assay (for example, with Atto532-tUI, from 2-60 nM). Dilution was also performed to reduce the concentrations of urea (<0.2 M), β-mercaptoethanol (<20 mM), hydrazine (<20 mM), which can otherwise interfere with binding by the sensor.
Negative control for the in-solution Ub pool assays. Samples were depleted of free Ub by incubation with excess E1, ATP and C1 (an adenosine sulfamate E1 inhibitor). E1 efficiently converts free Ub to a Ub-C1 C-terminal adduct 39 , which we expected would prevent binding to the sensor. Clarified cell lysate containing ~1.5 μM free Ub was incubated with 2 µM recombinant human E1 enzyme, 50 µM C1, 10 mM MgCl 2 and 250 µM ATP for 1 h at room temperature before addition of Atto532-tUI (see below) and fluorescence was measured. Relative to the untreated lysate, 95% of the Atto532-tUI fluorescence increase from addition of lysate was lost. Thus, non-specific binding accounts for no more than 5% of the sensor readout in the assays.
In-solution high-throughput assay to measure free Ub. Microplates (384-well SensoPlate Plus, Greiner Bio-One 781856) were used to measure free Ub concentrations of unknown samples in a high-throughput format. The plates were passivated by sequential treatment with 1% Hellmanex detergent, 1 M KOH and then 2% 1,7-dichloro-octamethyltetrasiloxane (Sigma-Aldrich) diluted in heptane, where each step was a 30 min soak followed by extensive washes with distilled water and finally air drying. Typically, 24 µl of a master mix containing 50 nM Atto532-tUI and assay buffer (200 mM sodium phosphate, pH 7.5, 50 mM NaCl, 2 mM DTT, 0.05% Brij35 and 0.2 mg ml −1 ovalbumin) was added to wells of the passivated 384-well plate. Then, to one set of wells, Ub standards were added and the remaining wells were used for samples (6 µl). Fluorescence intensities were quantified with a Typhoon FLA 9500 laser scanner (GE Healthcare). The Ub concentrations of unknown samples were determined by interpolating the fluorescent signals on standard curves generated by titration with a standard of free Ub.
Western blotting. Cells were lysed and prepared as for the in-solution pool assays. Lysate samples were separated by SDS-PAGE followed by western blotting onto nitrocellulose (0.2 μm, Bio-Rad). After blocking in PBS with 0.05% Tween-20 and 5% non-fat dry milk, membranes were incubated with anti-Ub (clone P4G7, Santa Cruz Biotechnology, 1:1,000 dilution) and anti-alpha tubulin (clone DMIA, Abcam, 1:50,000 dilution) mouse monoclonal antibodies overnight at 4 °C, washed with blocking buffer and then incubated with IRDye 680CW-conjugated goat antimouse (1:10,000, LI-COR) for 1 h. Imaging was done with a LI-COR Odyssey.
Sample preparation for microscopy. HeLa (ATCC), U2OS and MEF cells were cultured in DMEM (Gibco) supplemented with 10% (v/v) fetal bovine serum and 100 U ml −1 penicillin and 100 µg ml −1 streptomycin (Hyclone). RPE1 (ATCC) cells were cultured in DMEM/Ham's F-12, 50/50 mix (Corning). The U2OS and MEF cells used were previously described 53 . Cells were incubated for 1 h with 1 µM BTZ (Ubiquitin-Proteasome Biotechnologies), 10 µM E1 inhibitor (Compound 1; provided by Takeda Oncology) or vehicle alone (0.1% DMSO). Each experiment was performed a minimum of two times.
We fixed cells at <80% confluence with 4% paraformaldehyde in PBS for 30 min at 37 °C, permeabilized them with 0.1% Triton X-100 for 10 min at room temperature and blocked for 1 h with 5% BSA and 0.5% Tween-20 in PBS. Cells were stained for free Ub with 100 nM tUI-HA diluted in blocking solution for 30 min at room temperature. As a negative control, the sensor was pre-incubated for 5 min at room temperature with 100 μM Ub in blocking solution before addition to the samples. Next, cells were incubated overnight at 4 °C with anti-HA antibody (Sigma-Aldrich clone HA-7 or Bethyl Laboratories A190-108A; 1:1,000 dilution), stained with Alexa Fluor 568-conjugated goat anti-mouse IgG (Thermo Fisher; 1:500 dilution) and mounted on slides using ProLong Diamond Antifade medium (Thermo Fisher). Some coverslips were also stained with anti-Ub (clone FK2, Enzo Life Sciences; 1:1,000 dilution) or anti-K48 Ub (clone Apu2, Millipore; 1:200 dilution) primary antibodies and, subsequently, with Alexa Fluor 568-conjugated goat anti-mouse and Alexa Fluor 488-conjugated goat anti-rabbit (Thermo Fisher; 1:400 dilution) secondary antibodies. The HCS CellMask dye (Thermo Fisher) was added to the cells for 0.5 h as a marker of cell boundaries for high-content fluorescence intensity-based measurements.
Microscopy and image analysis. Cells were imaged using a Zeiss LSM 880 confocal microscope with C-Apochromat ×40/1.20 W or Plan-Apochromat ×63/1.40 Oil DIC M27 objectives. z-stack images were acquired with ZEN Black software (v.14.0.9.201) at 0.746 μm intervals. ImageJ 1.51 h (National Institute of Health, NIH) was used to perform maximum intensity projections of z-sections and to calculate cell mean fluorescence intensity values; cell contours were drawn using HCS CellMask dye as a reference and nuclei were identified with DAPI stain. Autofluorescence intensities recorded from unstained cells were subtracted from the tUI fluorescence. Three-dimensional reconstructions of RPE1 cells were obtained with Imaris software (v.9.1.1, Bitplane) from serial z-sections acquired at 0.242 µm increments. The Imaris surface creation tool was used to generate volume renderings and to quantify tUI fluorescence intensities in interphase and mitotic cells.
Statistical analysis.
Statistical calculations were performed with GraphPad Prism software and are described in the relevant figure legends. P values less than 0.05 were considered significant.
Material availability. Plasmids for bacterial expression of tUI, tUI-HA, tIVR and tISR are available from Addgene.org (Addgene ID 122661, 122662, 122663 and 122664, respectively).
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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